Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early parkinson disease [2]

Neurology

Volumn 71, Issue 6, 2008, Pages 462-463

  Shoulson, Ira ^a   Lang, Anthony E ^b   Bozyczko Coyne, Donna ^b  

^a Parkinson Study Group ^*

^b Parkinson Study Group

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CEP 1347; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MIXED LINEAGE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; TCH 346; UNCLASSIFIED DRUG; BRAIN DERIVED GROWTH FACTOR; CEP 11004; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE A; STRESS ACTIVATED PROTEIN KINASE; 3,9 BIS((ETHYLTHIO)METHYL) K 252A; 3,9-BIS((ETHYLTHIO)METHYL)-K-252A; CARBAZOLE DERIVATIVE; NEUROPROTECTIVE AGENT;

CELL DEATH; CELL PROTECTION; CELL SURVIVAL; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG TREATMENT FAILURE; LETTER; NERVE CELL; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL CULTURE; DISABILITY; ENZYME ACTIVATION; PROTEIN EXPRESSION; DRUG ANTAGONISM; HUMAN; NOTE; PATHOLOGY; TREATMENT FAILURE;

CARBAZOLES; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT FAILURE;

EID: 49049083497     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000324506.93877.5e     Document Type: Letter

References (8)

1. The Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69: 1480-1490.
2. Roux PP, Dorval G, Boudreau M, et al. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J Biol Chem 2002;277:49473-49480.
3. Wang LH, Paden AJ, Johnson EM, Jr. Mixed-lineage ki-nase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival. J Pharmacol Exp Ther 2005;312:1007-1019.
4. Enguita M, DeGregorio-Rocasolano N, Abad A, Trullas R. Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol Pharmacol 2005;67:1237-1246.
5. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recent clinical failures in Parkinson's disease with apo-ptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006;72:1197-1206.
6. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 2007;113-120.
7. Wang W, Yang Y, Ying C, et al. Inhibition of glycogen syn-thase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007;52:1678-1684.
8. Mocchetti I, Bachis A, Nosheny RL, Tanda G. Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons. Neurotox Res 2007;12:135-143.